Blog - Page 931 of 5708 - QualityStocks

ThursdayJul 28, 2022 11:57 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Dedicating Strategy Toward Acquisition, Creation of Lifesaving Medical Products

Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders, and brain concussion injuries. One drug product designed to treat mild traumatic injury within the first few minutes after an incident is advancing in a phase 1 clinical human trial following on preclinical lab animal tests that provided encouraging data, CEO Michael Redmond said in a June interview,” a recent article reads. “No U.S. Food and…

ThursdayJul 28, 2022 11:15 am

Cub Crafters Inc. Helps Recreational Travelers Take Flight with Classic Piper Cub-inspired Planes

Commercial airlines have seen a resurgence of air travel demand this year following two years of COVID restrictions that kept most people close to home, but many airlines found themselves overwhelmed by the crush of travelers and capped ticket availability Yakima, Washington based CubCrafters Inc. designs, builds, and tests unique light aircraft for those who want to fly themselves The company’s array of aircraft are inspired by the classic Piper PA-18 Super Cub and include a variety of the company’s own Cub-derivative, newly manufactured designs The light and ultralight aircraft market is expected to grow by the end of the…

ThursdayJul 28, 2022 10:53 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit https://ibn.fm/ghBjR To view…

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

ThursdayJul 28, 2022 9:45 am

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Increases to 19 Worldwide Lightning Network Nodes as FED Working Paper Supports Bitcoin Scalability Through the Network

LQwD is leveraging the Lightning Network for BTC scalability with 19 nodes active and the goal of creating Lightning Network node access in 24 countries by the end of this financial quarter LQwD nodes include US-West, Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, Australia, Japan-Osaka, France, Canada, England, and Japan The cryptocurrency market was valued at US $1.6 billion in 2021 and is expected to reach $2.2 billion by 2026, growing at a CAGR of 7.1% The Federal Reserve Bank of Cleveland Working Paper Series released Working Paper 22-19 in June 2022…

ThursdayJul 28, 2022 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on…

WednesdayJul 27, 2022 1:27 pm

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised with Strong In-Market Brand Portfolio, Cultivation and Export Capabilities

Flora Growth Corp. (NASDAQ: FLGC) recently reported that its board of directors had authorized the repurchase of up to $5 million of its outstanding common shares. “These recent developments highlight Flora management’s confidence in where the company is headed and its potential for growth as the year progresses. It also assures shareholders of the company’s commitment to driving shareholder value and exploring various opportunities to do so. As such, this only emphasizes Flora’s value as a good investment,” a recent article reads. “While making the announcement, Luis Merchan, Flora’s chairman and CEO, noted: ‘Flora continues to move assertively to execute…

WednesdayJul 27, 2022 1:13 pm

QualityStocksNewsBreaks – LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Making ‘Excellent Progress’ Toward Becoming Serious Network Participant

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a company focused on developing institution-grade payment infrastructure, liquidity and solutions for the Lightning Network (“LN”), has launched 17 nodes internationally, positioning itself to secure future routing fees in the rapidly expanding global payments network. “LQwD’s international node selection now includes Canada, France, Italy, Indonesia, Japan, England, Bahrain, South Africa, South Korea, Sweden, Singapore, Brazil, Germany, India, Ireland, Hong Kong, and the U.S. LQwD launched its first node in November 2021, US-West, and since that time, it has amassed a capacity of 5.78671656 BTC (US$118,805.11),” a recent article reads. “Since launching our first Lightning…

WednesdayJul 27, 2022 12:45 pm

DGE’s 9th Advancing Women’s Leadership Skills & Opportunities in Pharma & Healthcare

Aspiring medical professionals, influencers, solution providers, and executives of the pharma, biotech, medical device, and healthcare are invited to attend the 9th Advancing Women’s Leadership Skills & Opportunities In Pharma & Healthcare summit from September 19-21, 2022 in Philadelphia, PA. The DGE program focuses on the stories and insights of women executives who have reached the echelon of success after facing numerous challenges and hardships. The achievements of these women will inspire organizations to help close the gender disparity gap in the industry. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing B2B events. The…

WednesdayJul 27, 2022 12:04 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this…

Site Search

Company Search